arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Zoetis Inc.

ZTS
$77.23 ▲ +4.03 (+5.51%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
68
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

Zoetis Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $34.2B
Dividend Yield 2.63%
Revenue Growth 2.3%
Op. Margin
ROIC
FCF / Share $5.15
Trailing P/E 12.8x
Price / Book 9.9x
FCF Yield 6.7%
Debt / Equity 2.71
info Valuation on last close. End-of-day price, Aug 6, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.47B
↑ +2.3%
Net Income Profit after all expenses
$2.67B
↑ +7.5%
FCF / Share Free cash flow per share
$5.15
↑ +1.8%
Long-Term Debt Long-term obligations
$9.04B
↑ +73.2%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
88
Returns
99
Financial Health
9
Cash Quality
58

Dividend History

Dividend / share · sourced from SEC filings
$2.03 Latest / share
+13.0% YoY
+20.3% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 56 quarters